

Rowan University

## Rowan Digital Works

---

Rowan-Virtua Research Day

23rd Annual Research Day

---

May 2nd, 12:00 AM

### Amphotercin Washout of Fungal Peritonitis in Liver Transplant Recipient: A Novel Approach

Ann Thompson DO  
*Rowan University*

Mara Piltin DO  
*Rowan University*

Alyssa Imperatore DO  
*Rowan University*

Ely Sebastian MD

Sandra Paluzzi MD

Follow this and additional works at: [https://rdw.rowan.edu/stratford\\_research\\_day](https://rdw.rowan.edu/stratford_research_day)



Part of the [Fungi Commons](#), [Infectious Disease Commons](#), and the [Pharmaceutical Preparations Commons](#)

Let us know how access to this document benefits you - share your thoughts on our [feedback form](#).

---

Thompson, Ann DO; Piltin, Mara DO; Imperatore, Alyssa DO; Sebastian, Ely MD; and Paluzzi, Sandra MD, "Amphotercin Washout of Fungal Peritonitis in Liver Transplant Recipient: A Novel Approach" (2019). *Rowan-Virtua Research Day*. 6.  
[https://rdw.rowan.edu/stratford\\_research\\_day/2019/may2/6](https://rdw.rowan.edu/stratford_research_day/2019/may2/6)

This Poster is brought to you for free and open access by the Conferences, Events, and Symposia at Rowan Digital Works. It has been accepted for inclusion in Rowan-Virtua Research Day by an authorized administrator of Rowan Digital Works.

# Amphotericin B Washout of Fungal Peritonitis in Liver Transplant Recipient

Ann Thompson, D.O., Mara Piltin D.O., Alyssa Imperatore, D.O., Ely Sebastian, M.D. Sandra Paluzzi M.D..

Our Lady of Lourdes Medical Center.

## Background

Invasive fungal infection (IFI) has been shown to have significant prevalence as well as morbidity and mortality among the organ transplant recipient population. From 2001-2006 a prospective surveillance study consisting of 15 US transplant centers was conducted resulting in screening of 18,000 transplant recipients with identification of 1208 patients with invasive fungal infections. The pertinent results of the study showed an increase in fungal infections during the period of the study with an aim at focusing on the incidence, timing and mortality to improve prevention and treatment (1). From 2003-2012 a retrospective study identified 120 liver transplant recipients of which 13.5% were shown to have fungal infections (2). A review paper found a range in the literature of 5-42% of patients having at least one fungal infection post-transplant (3).

Fungal peritonitis is often difficult to diagnosis early due to lack of symptoms or specific clinical findings. Studies have shown that fungal infections usually occur within the first 3 months of liver transplantation. (1,4). The risk factors identified are multiple including, long continuous parenteral nutrition time, poorly controlled high blood sugar, long-term mechanical ventilation, rejection treatment, cytomegalovirus (CMV) viremia or disease, acute hepatic insufficiency, early graft failure, re-transplantation, prolonged preoperative hospitalization (particularly in the intensive care unit (ICU), preoperative use of broad-spectrum antibiotics, fungal colonization (2). A study with 152 liver recipients identified 2 independent risk factors for IFI as renal insufficiency requiring CVV or HD and correlation with the amount of fresh frozen plasma transfused (4). A review of 10 centers in Europe over 3 years in which 1208 liver transplants were performed resulted in 42 invasive fungal infections identified. The most significant risk factors were found to be respectively re-operation, presence of choledocojejunostomy and initial operating time of >8hrs (5).

## Patient Description

HPI: A 64 y/o female presented electively for orthotopic liver transplant.

Allergies: NKDA  
PMH: Cirrhosis, Hepatitis C, GERD, Bacterial peritonitis  
PSH: Cesarean section, Ventral hernia repair, Multiple paracentesis  
Social Hx: Former smoker, No ETOH or Drug use  
Fam Hx: Non-contributory

Pertinent clinical information:  
-Poor nutrition  
-Chronic hyponatremia  
-Nephrology recommendations for CVVHD in the OR until reperfusion of transplanted liver

## Intervention and Rationale

The patient continued to have significant ascites, requiring paracentesis which showed profound PMNs, signifying what was originally thought to be a secondary bacterial peritonitis with staph epidermidis from the cultures as a morbidity of the liver transplant however, further cultures resulted in identification of Candida species

A meta-analysis of 23 papers noted that abdominal washout with antibiotics compared to saline showed a significant decrease in morbidity (12).

Previous studies have also shown some successes with using direct application of antifungal medications including anti-fungal medication washout in patients with peritoneal dialysis catheters developing fungal peritonitis and also using antifungals for bladder irrigation in candiduria as well as intra-vitreal injections for fungal endophthalmitis (13,14).

An intraoperative discussion with the infectious disease team lead to the decision to use an amphotericin dwell during abdominal washout.

## Pre Intervention Bowel



## Operative Interventions

**Index Operation:** Orthotopic liver transplant with roux en y choledocojejunostomy biliary reconstruction and placement of gastrojejunostomy tube-Transfused 20UPRBC, 6FFP, 2 Platelets, 1 Cryo

POD 9 Dx Hand assisted laparoscopy for peritonitis, enterotomy with primary repair, revision reinforcement of jejunojejunostomy anastomosis

POD 22 Exploratory Laparotomy, saline washout, small bowel resection, removal of gastrojejunostomy tube, liver biopsy, placement of Abthera Vac

POD 24 Exploratory Laparotomy, saline washout, creation of end ileostomy, Dobhoff tube, Amphotericin B Dwell (30 min), Abthera Vac


POD 26 Exploratory Laparotomy, Saline washout, Right hemicolectomy, Amphotericin B Dwell (30 min), Abdominal wall closure with Wound Vac placement

POD 41 Sacral Wound Debridement

POD 103 Diagnostic Laparoscopy, Stamm Gastrojejunostomy feeding tube, EGD

POD 174 Exploratory Laparotomy, Ileostomy Takedown with Ileocolonic Anastomosis

## Response to Treatment



## Discussion

The patient progressed well after resolution of fungal infection and was at acute rehab at one point. However, now has returned to inpatient status. Invasive fungal infection still carries high morbidity and mortality among organ transplant recipients despite advances in techniques, medical care and immunosuppression  
It is reasonable based on prior studies showing success with abdominal washout and multiple uses of topical antifungal medications to use a multimodal approach with both intravenous medication and topical application of amphotericin B. The transplant patient is at higher of risk of complications due to immunosuppression and often multiple co-morbidities and/or malnutrition.This patient population should be considered for aggressive treatment measures with any complication.

## References

1. **Invasive Fungal Infections among Organ Transplant Recipients: Results of the Transplant-Associated Infection Surveillance Network (TRANSNET)** Peter G. Pappas Barbara D. Alexander David R. Andes Susan Hadley Carol A. Kauffman Alison Freifeld Elias J. Anaissie Lisa M. Brumble Loreen Herwaldt James Ito. *Clinical Infectious Diseases*, Volume 50, Issue 8, 15 April 2010, Pages 1101–1111, <https://doi.org/10.1086/651262> Published:15 April 2010
2. *Annals of Transplant*. 2012 Dec 31;17(4):59-63. **Fungal infection in patients after liver transplantation in years 2003 to 2012.**Yang CH<sup>1</sup>, He XS, Chen J, Ouyang B, Zhu XF, Chen MY, Xie WF, Chen L, Zheng DH, Zhong Y, Chen XX, Guan XD. *Int J Infect Dis*. 2011 May;15(5):e298-304. doi: 10.1016/j.ijid.2011.01.005. Epub 2011 Feb 22.
3. **Invasive fungal infections in liver transplantation** Xia Liu Zongxin Ling Lanjuan Li Bing Ruan Correspondence information about the author Bing Ruan. State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, Department of Infectious Diseases, the First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, Zhejiang, 310003, China  
*European Journal of Clinical Microbiology and Infectious Disease*. 1995 May;14(5):375-82.
3. **Risk factors for systemic fungal infections in liver transplant recipients.** Briegel J<sup>1</sup>, First H, Spill B.
4. **Invasive Candida Infections in Liver Transplant Recipients: Clinical Features and Risk Factors for Mortality** Bassetti, Matteo MD, PhD<sup>1</sup>, Peghin, Maddalena MD<sup>1</sup>, Carnelutti, Alessi. MD<sup>1</sup>; *Transplantation Direct*: May 2017 - Volume 3 - Issue 5 - p e156doi: 10.1097/TXD.0000000000000673Liver Transplantation
5. **Peritonitis After Liver Transplantation: Incidence, Risk Factors, Microbiology Profiles, and Outcome.** Surakit Pungpapong, Salvador Alvarez, Walter C. Hellinger Division of Gastroenterology and Hepatology, Department of Medicine, Division of Infectious Diseases, Department of Medicine, and Department of Transplantation, Mayo Clinic, Jacksonville,
6. **Transplant Research and Risk Management. Volume 6 Review Management of Candida infections in liver transplant recipients: current perspective.** Authors Linge Gowda PB, Tan BH Received 14 March 2014 Accepted for publication 12 May 2014. Published 7 July 2014 Volume 2014:6 Pages 45—53
7. *Transplantation*. 2003 Jun 27;75(12):2023-9. **Changes in the spectrum and risk factors for invasive candidiasis in liver transplant recipients: prospective, multicenter, case-controlled study.**Husain S<sup>1</sup>, Tolleran J, Dominguez EA, Baumgarten K, Humar A, Paterson DL, Wagener MM, Kusne S, Singh N.
8. *Liver Transplant*. 2006 May;12(5):850-8. **Antifungal prophylaxis in liver transplant patients: a systematic review and meta-analysis.** Cruciani M, Mengoli C, Malena M, Bosco O, Serpelloni G, Grossi
9. *Medical Mycology. Fungal infections in solid organ transplantation.* Fernanda P. Silveira, Shaïd Husain. Volume 45, Iss, ue 4, 1 June 2007, Pages 305–320, <https://doi.org/10.1080/13693780701200372> Published:01 June 2007
10. *Chin Med J (Engl)*. 2008 Apr 5;121(7):625-30. **Spectrum and risk factors for invasive candidiasis and non-Candida fungal infections after liver transplantation.** Shi SH<sup>1</sup>, Lu AW, Shen Y, Jia CK, Wang WL, Xie HY, Zhang M, Liang TB.
11. *Liver Transplant*. 2006 May;12(5):850-8. **Antifungal prophylaxis in liver transplant patients: a systematic review and meta-analysis.** Cruciani M, Mengoli C, Malena M.
12. *BJS. Meta-analysis of the effect of peritoneal lavage on survival in experimental peritonitis.* M. Qadan D. Dajani A. Dickinson H. C. Polk Jr. published: 12 January 2010 <https://doi.org/10.1002/bjs.6906>
13. *Ophthalmology*. 2008 Sept. ; 115(9): 1501-7. Wykoff CC, et. al. **Exogenous fungal endophthalmitis: Microbiology and Clinical Outcomes.** Department of ophthalmology, Bascom Palmer Eye Institute. University of Miami. Miller School of Medicine.
14. *Bladder Irrigation with Amphotericin B and Fungal Urinary Tract Infection: Systematic Review with Meta-Analysis.* Tuon FF, Amato VS, Penteado Filho SR. Centre for Reviews and Dissemination (UK). 1995